Regen BioPharma, Inc.
RGBP · OTC
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.10 | -0.06 | 0.04 |
| FCF Yield | -164.20% | -2.72% | -3.97% | -2.46% |
| EV / EBITDA | -2.96 | 5.77 | 5.52 | -7.62 |
| Quality | ||||
| ROIC | 9.52% | 15.80% | 5.03% | 2.03% |
| Gross Margin | 100.00% | 100.00% | 78.77% | 85.40% |
| Cash Conversion Ratio | 0.80 | -0.15 | -0.25 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.15% | 11.38% | 28.89% | 15.89% |
| Free Cash Flow Growth | -298.54% | 71.34% | 46.33% | -6,165.64% |
| Safety | ||||
| Net Debt / EBITDA | -1.95 | 0.52 | 0.41 | -0.45 |
| Interest Coverage | -1.69 | -2.22 | -1.33 | -0.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 6.14 | -180.52 | 394.07 | 466.54 |